---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-160340"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:27:59.112009+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IN8bio Phase 1 INB-200 data shows 100% of GBM patients exceed historical median PFS

## Summary
- 100% (8/8) patients exceeded historical median PFS of 4-7 months; two patients from three-dose cohort remain progression-free at 23.5 and 19.4 months.
- No treatment-related SAEs, DLTs, CRS, or ICANS reported; common TEAEs mild and linked to temozolomide.
- Cohort 1 PFS ranged 7.4–11.9 months; Cohort 3 first patient had 7.1 months PFS with no brain progression.
- Company on track to complete Phase 1 enrollment in 2023; further updates expected later this year.

## SEC filing metadata
- accession: 0001193125-23-160340
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523160340/0001193125-23-160340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523160340/d447037d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-160340
- JSON: https://secwatch.observer/filing/0001193125-23-160340.json
- Plain text: https://secwatch.observer/filing/0001193125-23-160340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.